Login Register Cart 0
Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

COL10A1 as a Prognostic Biomarker in Association with Immune Infiltration in Prostate Cancer

Author(s): Chenyang Wang, Jirong Wang, Siyu Chen, Kunpeng Li, Shun Wan and Li Yang*

Volume 24, Issue 3, 2024

Published on: 14 September, 2023

Page: [340 - 353] Pages: 14

DOI: 10.2174/1568009623666230817101809

Price: $65

Abstract

Background: The collagen type X alpha 1 (COL10A1) has recently been found to play an important role in the development and progression of cancer. However, the link between COL10A1 and the tumor immune microenvironment remains understood scantily.

Methods: In the current study, the pan-cancer data of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were used to investigate the expression mode, the clinical prognostic and diagnostic value of COL10A1 in different tumors. We used TCGA data to assess the correlations between COL10A1 and clinical symptoms of prostate cancer. The R packages “edgR” and “clusterProfiler” were used for differential expression gene and enrichment analysis of COL10A1. Immunohistochemistry was further employed to corroborate the expression of COL10A1 gene in prostate cancer. After that, we used TIMER to evaluate the pertinence of COL10A1 expression to immune infiltration level in prostate cancer.

Results: On the whole, COL10A1 was expressed at significantly higher levels in a variety of tumor tissues than in the corresponding normal tissues. Besides, significant correlations with tumor prognosis and relative exactitude in predicting tumors show that COL10A1 may be a probable prognostic and diagnostic biomarker of prostate cancer. In addition, the evidence indicates a significant correlation between COL10A1 and clinical symptoms of prostate cancer. Furthermore, the main molecular functions of COL10A1 included humoral immune response, complement activation, immunoglobulin, regulation of complement activation, and regulation of humoral immune response. Finally, we found that COL10A1 expression is positively correlated with enhanced macrophage and M2 macrophage infiltration in prostate cancer.

Conclusion: The study indicates that COL10A1 might participate in M2 macrophage polarization in prostate cancer. COL10A1 might be an innovative biomarker to evaluate tumor microenvironment immune cell infiltration and prognosis in prostate cancer.

« Previous Next »
Graphical Abstract

[1]
Gandaglia, G.; Leni, R.; Bray, F.; Fleshner, N.; Freedland, S.J.; Kibel, A.; Stattin, P.; Van Poppel, H.; La Vecchia, C. Epidemiology and prevention of prostate cancer. Eur. Urol. Oncol., 2021, 4(6), 877-892.
[http://dx.doi.org/10.1016/j.euo.2021.09.006] [PMID: 34716119]
[2]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[3]
Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin., 2022, 72(1), 7-33.
[http://dx.doi.org/10.3322/caac.21708] [PMID: 35020204]
[4]
Kohaar, I.; Petrovics, G.; Srivastava, S. A rich array of prostate cancer molecular biomarkers: Opportunities and challenges. Int. J. Mol. Sci., 2019, 20(8), 1813.
[http://dx.doi.org/10.3390/ijms20081813] [PMID: 31013716]
[5]
Khoo, A.; Liu, L.Y.; Nyalwidhe, J.O.; Semmes, O.J.; Vesprini, D.; Downes, M.R.; Boutros, P.C.; Liu, S.K.; Kislinger, T. Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry. Nat. Rev. Urol., 2021, 18(12), 707-724.
[http://dx.doi.org/10.1038/s41585-021-00500-1] [PMID: 34453155]
[6]
Rahmani, E.; Zaitlen, N.; Baran, Y.; Eng, C.; Hu, D.; Galanter, J.; Oh, S.; Burchard, E.G.; Eskin, E.; Zou, J.; Halperin, E. Sparse PCA corrects for cell type heterogeneity in epigenome-wide association studies. Nat. Methods, 2016, 13(5), 443-445.
[http://dx.doi.org/10.1038/nmeth.3809] [PMID: 27018579]
[7]
Ciccarese, C.; Massari, F.; Iacovelli, R.; Fiorentino, M.; Montironi, R.; Di Nunno, V.; Giunchi, F.; Brunelli, M.; Tortora, G. Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. Cancer Treat. Rev., 2017, 54, 68-73.
[http://dx.doi.org/10.1016/j.ctrv.2017.02.001] [PMID: 28231559]
[8]
Kielty, C.M.; Kwan, A.P.L.; Holmes, D.F.; Schor, S.L.; Grant, M.E. Type X collagen, a product of hypertrophic chondrocytes. Biochem. J., 1985, 227(2), 545-554.
[http://dx.doi.org/10.1042/bj2270545] [PMID: 4004779]
[9]
Chapman, K.B.; Prendes, M.J.; Sternberg, H.; Kidd, J.L.; Funk, W.D.; Wagner, J.; West, M.D. COL10A1 expression is elevated in diverse solid tumor types and is associated with tumor vasculature. Future Oncol., 2012, 8(8), 1031-1040.
[http://dx.doi.org/10.2217/fon.12.79] [PMID: 22894674]
[10]
Huang, H.; Li, T.; Ye, G.; Zhao, L.; Zhang, Z.; Mo, D.; Wang, Y.; Zhang, C.; Deng, H.; Li, G.; Liu, H. High expression of COL10A1 is associated with poor prognosis in colorectal cancer. OncoTargets Ther., 2018, 11, 1571-1581.
[http://dx.doi.org/10.2147/OTT.S160196] [PMID: 29593423]
[11]
Liu, Q.; Diao, R.; Feng, G.; Mu, X.; Li, A. Risk score based on three mRNA expression predicts the survival of bladder cancer. Oncotarget, 2017, 8(37), 61583-61591.
[http://dx.doi.org/10.18632/oncotarget.18642] [PMID: 28977887]
[12]
Yu, G.; Wang, L.G.; Han, Y.; He, Q.Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS, 2012, 16(5), 284-287.
[http://dx.doi.org/10.1089/omi.2011.0118] [PMID: 22455463]
[13]
Li, T.; Fan, J.; Wang, B.; Traugh, N.; Chen, Q.; Liu, J.S.; Li, B.; Liu, X.S. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res., 2017, 77(21), e108-e110.
[http://dx.doi.org/10.1158/0008-5472.CAN-17-0307] [PMID: 29092952]
[14]
Bindea, G.; Mlecnik, B.; Tosolini, M.; Kirilovsky, A.; Waldner, M.; Obenauf, A.C.; Angell, H.; Fredriksen, T.; Lafontaine, L.; Berger, A.; Bruneval, P.; Fridman, W.H.; Becker, C.; Pagès, F.; Speicher, M.R.; Trajanoski, Z.; Galon, J. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity, 2013, 39(4), 782-795.
[http://dx.doi.org/10.1016/j.immuni.2013.10.003] [PMID: 24138885]
[15]
He, Y.; Siebuhr, A.S.; Brandt-Hansen, N.U.; Wang, J.; Su, D.; Zheng, Q.; Simonsen, O.; Petersen, K.K.; Arendt-Nielsen, L.; Eskehave, T.; Hoeck, H.C.; Karsdal, M.A.; Bay-Jensen, A.C. Type X collagen levels are elevated in serum from human osteoarthritis patients and associated with biomarkers of cartilage degradation and inflammation. BMC Musculoskelet. Disord., 2014, 15(1), 309.
[http://dx.doi.org/10.1186/1471-2474-15-309] [PMID: 25245039]
[16]
Zhang, M.; Chen, H.; Wang, M.; Bai, F.; Wu, K. Bioinformatics analysis of prognostic significance of COL10A1 in breast cancer. Biosci. Rep., 2020, 40(2), BSR20193286.
[http://dx.doi.org/10.1042/BSR20193286] [PMID: 32043519]
[17]
Liang, Y.; Xia, W.; Zhang, T.; Chen, B.; Wang, H.; Song, X.; Zhang, Z.; Xu, L.; Dong, G.; Jiang, F. Upregulated collagen COL10A1 remodels the extracellular matrix and promotes malignant progression in lung adenocarcinoma. Front. Oncol., 2020, 10, 573534.
[http://dx.doi.org/10.3389/fonc.2020.573534] [PMID: 33324550]
[18]
Shen, G. The role of type X collagen in facilitating and regulating endochondral ossification of articular cartilage. Orthod. Craniofac. Res., 2005, 8(1), 11-17.
[http://dx.doi.org/10.1111/j.1601-6343.2004.00308.x] [PMID: 15667640]
[19]
Grskovic, I.; Kutsch, A.; Frie, C.; Groma, G.; Stermann, J.; Schlötzer-Schrehardt, U.; Niehoff, A.; Moss, S.E.; Rosenbaum, S.; Pöschl, E.; Chmielewski, M.; Rappl, G.; Abken, H.; Bateman, J.F.; Cheah, K.S.E.; Paulsson, M.; Brachvogel, B. Depletion of annexin A5, annexin A6, and collagen X causes no gross changes in matrix vesicle-mediated mineralization, but lack of collagen X affects hematopoiesis and the Th1/Th2 response. J. Bone Miner. Res., 2012, 27(11), 2399-2412.
[http://dx.doi.org/10.1002/jbmr.1682] [PMID: 22692895]
[20]
Li, T.; Huang, H.; Shi, G.; Zhao, L.; Li, T.; Zhang, Z.; Liu, R.; Hu, Y.; Liu, H.; Yu, J.; Li, G. TGF-β1-SOX9 axis-inducible COL10A1 promotes invasion and metastasis in gastric cancer via epithelial-to-mesenchymal transition. Cell Death Dis., 2018, 9(9), 849.
[http://dx.doi.org/10.1038/s41419-018-0877-2] [PMID: 30154451]
[21]
Zhao, J.; Wang, R.; Sun, X.; Huang, K.; Jin, J.; Lan, L.; Jian, Y.; Xu, Z.; Wu, H.; Wang, S.; Wang, J. An integrative multi-omics analysis based on nomogram for predicting prostate cancer bone metastasis incidence. Genet. Res., 2022, 2022, 1-17.
[http://dx.doi.org/10.1155/2022/8213723] [PMID: 36245556]
[22]
Bautmans, I.; Knoop, V.; Amuthavalli, T.J.; Maier, A.B.; Beard, J.R.; Freiberger, E.; Belsky, D.; Aubertin-Leheudre, M.; Mikton, C.; Cesari, M.; Sumi, Y.; Diaz, T.; Banerjee, A. WHO working definition of vitality capacity for healthy longevity monitoring. Lancet Healthy Longev., 2022, 3(11), e789-e796.
[http://dx.doi.org/10.1016/S2666-7568(22)00200-8] [PMID: 36356628]
[23]
Jaratlerdsiri, W.; Jiang, J.; Gong, T.; Patrick, S.M.; Willet, C.; Chew, T.; Lyons, R.J.; Haynes, A.M.; Pasqualim, G.; Louw, M.; Kench, J.G.; Campbell, R.; Horvath, L.G.; Chan, E.K.F.; Wedge, D.C.; Sadsad, R.; Brum, I.S.; Mutambirwa, S.B.A.; Stricker, P.D.; Bornman, M.S.R.; Hayes, V.M. African-specific molecular taxonomy of prostate cancer. Nature, 2022, 609(7927), 552-559.
[http://dx.doi.org/10.1038/s41586-022-05154-6] [PMID: 36045292]
[24]
Zhang, R.; Liu, Q.; Li, T.; Liao, Q.; Zhao, Y. Role of the complement system in the tumor microenvironment. Cancer Cell Int., 2019, 19(1), 300.
[http://dx.doi.org/10.1186/s12935-019-1027-3] [PMID: 31787848]
[25]
Wang, C.; Liu, S.; Zhang, X.; Wang, Y.; Guan, P.; Bu, F.; Wang, H.; Wang, D.; Fan, Y.; Hou, S.; Qiu, Z. SKA3 is a prognostic biomarker and associated with immune infiltration in bladder cancer. Hereditas, 2022, 159(1), 20.
[http://dx.doi.org/10.1186/s41065-022-00234-z] [PMID: 35546682]
[26]
Kerneur, C.; Cano, C.E.; Olive, D. Major pathways involved in macrophage polarization in cancer. Front. Immunol., 2022, 13, 1026954.
[http://dx.doi.org/10.3389/fimmu.2022.1026954] [PMID: 36325334]
[27]
Patysheva, M.; Frolova, A.; Larionova, I.; Afanas’ev, S.; Tarasova, A.; Cherdyntseva, N.; Kzhyshkowska, J. Monocyte programming by cancer therapy. Front. Immunol., 2022, 13, 994319.
[http://dx.doi.org/10.3389/fimmu.2022.994319] [PMID: 36341366]
[28]
He, Y.; de Araújo Júnior, R.F.; Cruz, L.J.; Eich, C. Functionalized nanoparticles targeting tumor-associated macrophages as cancer therapy. Pharmaceutics, 2021, 13(10), 1670.
[http://dx.doi.org/10.3390/pharmaceutics13101670] [PMID: 34683963]
[29]
Schwarz, E.; Carson, W.E., III Analysis of potential biomarkers of response to IL-12 therapy. J. Leukoc. Biol., 2022, 112(3), 557-567.
[http://dx.doi.org/10.1002/JLB.5RU1221-675R] [PMID: 35790025]
[30]
Tian, L.; Lei, A.; Tan, T.; Zhu, M.; Zhang, L.; Mou, H.; Zhang, J. Macrophage-based combination therapies as a new strategy for cancer immunotherapy. Kidney Dis., 2022, 8(1), 26-43.
[http://dx.doi.org/10.1159/000518664] [PMID: 35224005]
[31]
Yagi, T.; Baba, Y.; Okadome, K.; Kiyozumi, Y.; Hiyoshi, Y.; Ishimoto, T.; Iwatsuki, M.; Miyamoto, Y.; Yoshida, N.; Watanabe, M.; Komohara, Y.; Baba, H. Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer. Eur. J. Cancer, 2019, 111, 38-49.
[http://dx.doi.org/10.1016/j.ejca.2019.01.018] [PMID: 30822683]
[32]
Xue, Y.; Tong, L.; LiuAnwei Liu, F.; Liu, A.; Zeng, S.; Xiong, Q.; Yang, Z.; He, X.; Sun, Y.; Xu, C. Tumor-infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer. Oncol. Rep., 2019, 42(2), 581-594.
[http://dx.doi.org/10.3892/or.2019.7196] [PMID: 31233191]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy